MiniMed (MMED) Cash & Equivalents (2025 - 2026)

MiniMed (MMED) posted Cash & Equivalents of $207.0 million for Q3 2026, down 30.54% quarter-over-quarter from $298.0 million in Q2 2026.

Analysis

MiniMed (MMED) Cash & Equivalents (2025 - 2026) Analysis & Trends

MiniMed (MMED) has 2 years of Cash & Equivalents data on file, last reported at $207.0 million in Q3 2026.

For the quarter ending Q3 2026, Cash & Equivalents changed N/A year-over-year to $207.0 million; the trailing twelve-month figure through Jul 2026 stood at $207.0 million (changed N/A YoY), and the FY2026 full-year result was $298.0 million, up 2609.09% from the prior year.
Cash & Equivalents was $207.0 million for Q3 2026 at MiniMed, down from $298.0 million in the prior quarter.
In the past five years, Cash & Equivalents ranged from a high of $298.0 million in Q2 2026 to a low of $10.0 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Abbott Laboratories	183.04 Bn	177.44 Bn	7.27 Bn	5.10 Bn
2	Intuitive Surgical	125.02 Bn	119.81 Bn	1.96 Bn	2.76 Bn
3	Medtronic	117.84 Bn	109.02 Bn	6.34 Bn	1.69 Bn
4	Stryker	105.50 Bn	102.02 Bn	4.50 Bn	3.39 Bn
5	Boston Scientific	66.27 Bn	65.73 Bn	3.85 Bn	539.00 Mn
6	Edwards Lifesciences	49.60 Bn	45.35 Bn	1.35 Bn	2.91 Bn
7	Alcon	33.70 Bn	32.24 Bn	1.68 Bn	1.36 Bn
8	Dexcom	32.06 Bn	30.11 Bn	830.00 Mn	1.11 Bn
9	Steris	21.02 Bn	20.54 Bn	684.20 Mn	482.30 Mn
10	MiniMed	6.37 Bn	6.17 Bn	465.00 Mn	207.00 Mn

Historic Data

Download Data